As is the case of METTL3 in glioblastoma, METTL14 depletion facilitates the malignant phenotype, characterized by upregulated oncogenes such as ADAM19 and reduced expression of tumor suppressors such as CDKN2A (42). This evidence concerns the gene ADAM19 and glioblastoma.